Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Dana-Farber Cancer Institute

Sites in Boston, MA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 6:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1323
Shown on this page
12
Current sort
Recently updated
Campus scope
Dana-Farber Cancer Institute, Boston, MA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Dana-Farber Cancer Institute, Boston, MA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 469–480 of 1,323 matching trials with a site at Dana-Farber Cancer Institute, Boston, MA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 3 Interventional Results available

177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

NCT04689828
Site status not listed — check the official record
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
20
States / cities
Denver, Colorado • Gainesville, Florida • New Orleans, Louisiana + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 27, 2026, 6:34 PM EDT
Recruiting Phase 1Phase 2 Interventional

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

NCT04870944
Status at this site: Recruiting
View directory record Official record
Conditions
Diffuse Midline Glioma, H3 K27-Altered, Metastatic Malignant Neoplasm in the Central Nervous System, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Midline Glioma, H3 K27-Altered, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Primary Malignant Central Nervous System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Primary Malignant Central Nervous System Neoplasm
Interventions
Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Echocardiography Test, FACT Complex-targeting Curaxin CBL0137
Procedure · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 21 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
34
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 27, 2026, 6:34 PM EDT
Active, not recruiting Phase 3 Interventional

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

NCT06047080
Site status not listed — check the official record
View directory record Official record
Conditions
Large B-Cell Lymphoma
Interventions
Glofitamab, Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
60
States / cities
Anchorage, Alaska • Anaheim, California • Clovis, California + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 27, 2026, 6:34 PM EDT
Recruiting Not applicable Interventional

Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial

NCT06202183
Status at this site: Recruiting
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Colon Cancer, Metastatic Colorectal Cancer
Interventions
Exercise Program
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 27, 2026, 6:34 PM EDT
Recruiting Not applicable Interventional

Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial

NCT06040125
Status at this site: Not yet recruiting
View directory record Official record
Conditions
PROSTATE CANCER, Metastatic Prostate Cancer, Metastatic Prostate Carcinoma
Interventions
Supervised Circuit Training
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 27, 2026, 6:34 PM EDT
Active, not recruiting Phase 1 Interventional

Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases

NCT05552469
Site status not listed — check the official record
View directory record Official record
Conditions
Myeloid Diseases
Interventions
DFV890
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
11
States / cities
Stanford, California • Tampa, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 27, 2026, 6:34 PM EDT
Recruiting Not applicable Interventional

Resilience and Equity in Aging, Cancer, and Health (REACH)

NCT04674267
Status at this site: Recruiting
View directory record Official record
Conditions
Gastric Cancer, Colon Cancer, Esophageal Cancer, Rectal Cancer, Pancreatic Cancer, Gastrointestinal Cancer
Interventions
Phase 2 Intervention - Geriatric Co-Management
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
65 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 27, 2026, 6:34 PM EDT
Not yet recruiting Not applicable Interventional

A Structured Peer Support Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation

NCT07774104
Site status not listed — check the official record
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation
Interventions
STEPP, Minimally Enhanced Usual Care Control
Behavioral · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Tampa, Florida • Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 27, 2026, 6:34 PM EDT
Recruiting Phase 1Phase 2 Interventional

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

NCT03104491
Status at this site: Recruiting
View directory record Official record
Conditions
Acute Lymphocytic Leukemia
Interventions
Inotuzumab Ozogamicin
Drug
Lead sponsor
Leland Metheny
Other
Eligibility
16 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
7
States / cities
Westwood, Kansas • Boston, Massachusetts • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 27, 2026, 6:34 PM EDT
Recruiting Not applicable Interventional

Positive Psychology Intervention for Hematopoietic Stem Cell Transplantation Survivors

NCT06328127
Status at this site: Recruiting
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplant
Interventions
PATH
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
3
States / cities
Tampa, Florida • Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 27, 2026, 6:34 PM EDT
Recruiting Not applicable Interventional

Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing

NCT06907797
Status at this site: Recruiting
View directory record Official record
Conditions
Acute Leukemia, Leukemia
Interventions
TRIAL Web-Based Application
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 27, 2026, 6:34 PM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

NCT06854653
Status at this site: Recruiting
View directory record Official record
Conditions
CTCL
Interventions
PTX-100
Drug
Lead sponsor
Prescient Therapeutics, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Duarte, California • Irvine, California • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 27, 2026, 6:34 PM EDT

About this Dana-Farber Cancer Institute institution page

What this page lists
ClinicalTrials.gov records that list Dana-Farber Cancer Institute in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Dana-Farber Cancer Institute at any site, browse by condition, or browse by U.S. city.